Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accounts Payables: 2009-2024

Historic Accounts Payables for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $20.4 million.

  • Cytokinetics' Accounts Payables rose 90.69% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 90.69%. This contributed to the annual value of $20.4 million for FY2024, which is 5.29% down from last year.
  • Latest data reveals that Cytokinetics reported Accounts Payables of $20.4 million as of FY2024, which was down 5.29% from $21.5 million recorded in FY2023.
  • Cytokinetics' Accounts Payables' 5-year high stood at $25.6 million during FY2022, with a 5-year trough of $8.1 million in FY2020.
  • In the last 3 years, Cytokinetics' Accounts Payables had a median value of $21.5 million in 2023 and averaged $22.5 million.
  • Per our database at Business Quant, Cytokinetics' Accounts Payables surged by 161.95% in 2021 and then declined by 16.02% in 2023.
  • Over the past 5 years, Cytokinetics' Accounts Payables (Yearly) stood at $8.1 million in 2020, then surged by 161.95% to $21.1 million in 2021, then grew by 21.45% to $25.6 million in 2022, then decreased by 16.02% to $21.5 million in 2023, then dropped by 5.29% to $20.4 million in 2024.